{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:04:01Z","timestamp":1789585441172,"version":"build-2803163510"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hemolytic anemia (HA) is a frequent condition with variable pathophysiology. Hematopoietic stem cell transplantation (HSCT) is unique because it is performed across the ABO blood group barrier. Thereby, there is a transfer of plasma, red blood cells, and immunocompetent cells from the donor to the recipient, possibly leading to HA, due to red blood cell incompatibility. The underlying disease, drugs (particularly those used for conditioning and immunosuppressants), infections, graft-versus-host disease, and autoimmune diseases may all contribute to the clinical and laboratory picture of HA. Additionally, transplantation-associated thrombotic microangiopathy (TA-TMA) may occur and is associated with significant morbidity and mortality. This review highlights the current knowledge on HA after allogeneic HSCT, particularly due to ABO incompatibility. We follow the timeline of the transplantation process and discuss investigations, differential diagnosis, and prophylactic measures including graft processing to avoid hemolysis in case of ABO incompatibility. Finally, current therapeutic approaches for both TA-TMA and post-HSCT autoimmune HA, which are associated with high morbidity and mortality, are discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.378","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Management of hemolytic anemia following allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"2015","author":[{"given":"Andreas","family":"Holbro","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital, Basel, Switzerland; and"},{"name":"Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob R.","family":"Passweg","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111704055623100_B1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111704055623100_B2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol"},{"key":"2019111704055623100_B3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/asheducation-2005.1.58","article-title":"An evidence-based approach to the treatment of adults with sickle cell disease","author":"Lottenberg","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2019111704055623100_B4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"key":"2019111704055623100_B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","author":"Garratty","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2019111704055623100_B6","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1182\/blood-2007-10-118372","article-title":"A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation","volume":"112","author":"Gajewski","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111704055623100_B7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO-incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111704055623100_B8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/bmt.2011.135","article-title":"Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation","volume":"46","author":"Rowley","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111704055623100_B9","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1182\/blood.V86.7.2842.2842","article-title":"Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease","volume":"86","author":"Korbling","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2019111704055623100_B10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V60.2.420.bloodjournal602420","article-title":"Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion","volume":"60","author":"Braine","year":"1982","journal-title":"Blood"},{"key":"2019111704055623100_B11","article-title":"AABB. Apheresis: principles and practice","author":"McLeod","year":"2010","edition":"Ed 3"},{"issue":"2","key":"2019111704055623100_B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1537-2995.2011.03295.x","article-title":"Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange","volume":"52","author":"Curley","year":"2012","journal-title":"Transfusion"},{"issue":"2","key":"2019111704055623100_B13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.13356","article-title":"Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins","volume":"94","author":"Stussi","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111704055623100_B14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"issue":"5","key":"2019111704055623100_B15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2141.2005.05364.x","article-title":"Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation","volume":"128","author":"Griffith","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704055623100_B16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbmt.2012.10.012","article-title":"Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation","volume":"19","author":"Meyer","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111704055623100_B17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1537-2995.2011.03069.x","article-title":"How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?","volume":"51","author":"Daniel-Johnson","year":"2011","journal-title":"Transfusion"},{"issue":"3","key":"2019111704055623100_B18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.1365-2141.2001.02587.x","article-title":"Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility","volume":"112","author":"Bolan","year":"2001","journal-title":"Br J Haematol"},{"issue":"3 Pt 2","key":"2019111704055623100_B19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1423-0410.2009.01292.x","article-title":"Transfusion policy in ABO-incompatible allogeneic stem cell transplantation","volume":"98","author":"Worel","year":"2010","journal-title":"Vox Sang"},{"issue":"12","key":"2019111704055623100_B20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bmt.1703074","article-title":"Immune hemolysis involving non-ABO\/RhD alloantibodies following hematopoietic stem cell transplantation","volume":"27","author":"Young","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111704055623100_B21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.bmt.1704524","article-title":"Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Franchini","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111704055623100_B22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1537-2995.1999.39299154733.x","article-title":"ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation","volume":"39","author":"Benjamin","year":"1999","journal-title":"Transfusion"},{"issue":"11-12","key":"2019111704055623100_B23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1537-2995.1999.39111273.x","article-title":"ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity","volume":"39","author":"Benjamin","year":"1999","journal-title":"Transfusion"},{"key":"2019111704055623100_B24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cei.12518","article-title":"Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis","volume":"178","author":"Bonilla","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"2019111704055623100_B25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111704055623100_B26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111704055623100_B27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"2019111704055623100_B28","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111704055623100_B29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705758","article-title":"Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?","volume":"40","author":"Batts","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111704055623100_B30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"5","key":"2019111704055623100_B31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"2019111704055623100_B32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.beha.2008.02.002","article-title":"Vascular endothelium as \u201cnovel\u201d target of graft-versus-host disease","volume":"21","author":"Tichelli","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2019111704055623100_B33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.beha.2008.12.002","article-title":"Thrombotic complications after haematopoietic stem cell transplantation: early and late effects","volume":"22","author":"Tsakiris","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2019111704055623100_B34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2019111704055623100_B35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"issue":"2","key":"2019111704055623100_B36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/trf.12859","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options","volume":"55","author":"Kim","year":"2015","journal-title":"Transfusion"},{"issue":"9","key":"2019111704055623100_B37","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"issue":"11","key":"2019111704055623100_B38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1705160","article-title":"Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants","volume":"36","author":"Martinez","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111704055623100_B39","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111704055623100_B40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute graft-versus-host disease: a bench-to-bedside update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111704055623100_B41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1537-2995.2003.00282.x","article-title":"Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A","volume":"43","author":"Sarkodee-Adoo","year":"2003","journal-title":"Transfusion"},{"issue":"3","key":"2019111704055623100_B42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2141.2012.09070.x","article-title":"Management of autoimmune diseases after haematopoietic stem cell transplantation","volume":"157","author":"Holbro","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111704055623100_B43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","article-title":"Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party","volume":"118","author":"Daikeler","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111704055623100_B44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-07-445965","article-title":"New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Daikeler","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111704055623100_B45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.bmt.1705641","article-title":"Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients","volume":"39","author":"Sanz","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111704055623100_B46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbmt.2013.11.014","article-title":"Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience","volume":"20","author":"Faraci","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111704055623100_B47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2014.09.009","article-title":"Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital","volume":"21","author":"Wang","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111704055623100_B48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1399-3046.2007.00711.x","article-title":"Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient","volume":"11","author":"Brunner","year":"2007","journal-title":"Pediatr Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/378\/1251211\/bep00115000378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/378\/1251211\/bep00115000378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:06:36Z","timestamp":1573981596000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/378\/20753\/Management-of-hemolytic-anemia-following"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.378","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}